Mylan N.V. with ticker code (MYL) have now 16 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 35 and 18 calculating the mean target price we have 25.81. With the stocks previous close at 19.79 this now indicates there is a potential upside of 30.4%. The 50 day MA is 18.35 and the 200 moving average now moves to 18.95. The company has a market capitalisation of $10,281m. You can visit the company’s website by visiting: http://www.mylan.com
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women’s health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer ; Momenta Pharmaceuticals; TB Alliance; Theravance Biopharma; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Hatfield, the United Kingdom.